HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
1 . A conjugate comprising an active agent coupled, via a linker, to an HSP90 targeting moiety, wherein the active agent is a PI3K inhibitor and wherein the PI3K inhibitor is selected from the group consisting of BGT-226 (NVP-BGT226), PF-05212384, PF-04691502, and fragments/derivatives/analogs thereof.
2 . The conjugate of claim 1 , wherein the HSP90 targeting moiety is an HSP90 inhibitor.
3 . The conjugate of claim 2 , wherein the HSP90 inhibitor is a small molecule.
4 . The conjugate of claim 3 , wherein the HSP90 inhibitor is selected from the group consisting of Ganetespib, Luminespib (AUY-922, NVP-AUY922), Debio-0932, MPC-3100, or Onalespib (AT-13387), SNX-2112, 17-amino-geldanamycin hydroquinone, PU-H71, AT13387, and derivatives/analogs thereof.
5 . The conjugate of claim 1 , wherein the HSP90 targeting moiety is ganetespib or a derivative thereof.
6 . The conjugate of claim 1 , wherein the HSP90 targeting moiety comprises a structure of
7 . The conjugate of claim 1 , wherein the linker comprises an ester group, a disulfide group, an amide group, an acylhydrazone group, an ether group, a carbamate group, a carbonate group, or an urea group.
8 . The conjugate of claim 1 , wherein the linker is a cleavable linker.
9 . The conjugate of claim 1 , wherein the conjugate has a molecular weight of less than about 50,000 Da, less than about 40,000 Da, less than about 30,000 Da, less than about 20,000 Da, less than about 15,000 Da, less than about 10,000 Da, less than about 8,000 Da, less than about 5,000 Da, less than about 3,000 Da, less than 2000 Da, less than 1500 Da, less than 1000 Da, or less than 500 Da.
10 . The conjugate of claim 1 , wherein the conjugate comprises PF-05212384 or its fragment/derivative/analog and ganetespib or its derivative.
11 . The conjugate of claim 10 , wherein the conjugate is selected from the group consisting of Conjugate 18, Conjugate 19, Conjugate 20, and Conjugate 21, or a pharmaceutically acceptable salt thereof.
12 . The conjugate of claim 1 , wherein the conjugate comprises BGT-226 or its fragment/derivative/analog and ganetespib or its derivative.
13 . The conjugate of claim 12 , wherein the conjugate is selected from the group consisting of Conjugate 22, Conjugate 23, Conjugate 24, Conjugate 25, and Conjugate 26, or a pharmaceutically acceptable salt thereof.
14 . The conjugate of claim 1 , further comprising a permeability modulating unit.
15 . The conjugate of claim 1 , further comprising a pharmacokinetic modulating unit.
16 . A pharmaceutical composition comprising the conjugate of claim 1 and at least one pharmaceutically acceptable excipient.
17 . A method of reducing cell proliferation comprising administering a therapeutically effective amount of at least one conjugate of claim 1 to the cell.
18 . The method of claim 17 , wherein the cell is a cancer cell.
19 . The method of claim 18 , wherein the cancer cell is a small-cell lung cancer cell, a non-small-cell lung cancer cell, a sarcoma cell, a pancreatic cancer cell, a breast cancer cell, or a colon cancer cell.
20 . A method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 16 .
21 . The method of claim 20 , wherein the cancer is small-cell lung cancer cell, a non-small-cell lung cancer cell, a sarcoma cell, a pancreatic cancer cell, a breast cancer cell, or a colon cancer cell.